BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 12879693)

  • 1. A novel RIPK1 inhibitor attenuates GVHD.
    Hill GR; Koyama M
    Blood; 2023 Mar; 141(9):969-970. PubMed ID: 36862437
    [No Abstract]   [Full Text] [Related]  

  • 2. Paving the way towards universal treatment with allogenic T cells.
    Townsend MH; Bennion K; Robison RA; O'Neill KL
    Immunol Res; 2020 Feb; 68(1):63-70. PubMed ID: 32096010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect.
    Imado T; Iwasaki T; Kuroiwa T; Sano H; Hara H
    Transplantation; 2004 Feb; 77(3):391-8. PubMed ID: 14966413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
    Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
    Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
    Yang I; Weiss L; Abdul-Hai A; Kasir J; Reich S; Slavin S
    Cancer Res; 2005 Nov; 65(21):9735-40. PubMed ID: 16266994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunosuppressive drugs in the prevention and treatment of GVHD after allogenic bone marrow transplantation].
    Basić-Jukić N; Labar B
    Acta Med Croatica; 2003; 57(2):131-9. PubMed ID: 12879693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease.
    Margolis J; Vogelsang G
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):72-7. PubMed ID: 10877057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of graft-versus-host disease: role of regulatory T lymphocytes.
    Hess AD
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):13-21. PubMed ID: 16399597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG).
    Lazarus HM; Vogelsang GB; Rowe JM
    Bone Marrow Transplant; 1997 Mar; 19(6):577-600. PubMed ID: 9085738
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.